APA

van Andel L., Rosing H., Tibben M. M., Lucas L., Lubomirov R., Avilés P., Francesch A., Fudio S., Gebretensae A., Hillebrand M. J. X., Schellens J. H. M. & Beijnen J. H. (20190809). Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of. : Cancer chemotherapy and pharmacology.

Chicago

van Andel L, Rosing H, Tibben M M, Lucas L, Lubomirov R, Avilés P, Francesch A, Fudio S, Gebretensae A, Hillebrand M J X, Schellens J H M and Beijnen J H. 20190809. Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of. : Cancer chemotherapy and pharmacology.

Harvard

van Andel L., Rosing H., Tibben M. M., Lucas L., Lubomirov R., Avilés P., Francesch A., Fudio S., Gebretensae A., Hillebrand M. J. X., Schellens J. H. M. and Beijnen J. H. (20190809). Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of. : Cancer chemotherapy and pharmacology.

MLA

van Andel L, Rosing H, Tibben M M, Lucas L, Lubomirov R, Avilés P, Francesch A, Fudio S, Gebretensae A, Hillebrand M J X, Schellens J H M and Beijnen J H. Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of. : Cancer chemotherapy and pharmacology. 20190809.